Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers
NCT05750355
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy Subjects
Interventions
DRUG:
TPN171H 10 mg Group
DRUG:
TPN171H 30 mg Group
DRUG:
TPN171H 40 mg Group
DRUG:
TPN171H 50 mg Group
Sponsor
Vigonvita Life Sciences